PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jexpmedHomeThe Rockefeller University PressEditorsContactInstructions for AuthorsThis issue
 
J Exp Med. 1990 January 1; 171(1): 197–210.
PMCID: PMC2187674

In vivo treatment with monoclonal antibody 3.2.3 selectively eliminates natural killer cells in rats

Abstract

We recently described a mAb 3.2.3 (IgG1), that recognizes a 60-kD dimeric molecule expressed exclusively on fresh and rIL-2-activated NK cells and polymorphonuclear cells. mAb 3.2.3 enhances cytolytic activity of NK cells against selected FcR+ tumor target cells by reverse antibody-dependent cellular cytotoxicity (ADCC), indicating that it recognizes an important triggering site on NK cells. The in vivo treatment of F344 rats with mAb 3.2.3 intraperitoneally completely and selectively eliminated NK/ADCC function in the spleen and peripheral blood for up to 10 d after treatment. Total numbers and percentages of T cells, monocytes, or PMN were not decreased and T cell function, as determined by Con A stimulation, was not affected. The reduction in NK function was associated with a decrease in the numbers of LGL and the expression of other NK-related cell surface markers including CD2, CD8, and asialo GM1. Depletion of NK cells with 3.2.3 markedly decreased the survival of F344 rats injected intravenously with MADB106 mammary adenocarcinoma cells, but did not affect the subcutaneous growth of MADB106 tumors. These results indicate that mAb 3.2.3 (in contrast to anti-asialo GM1 and OX8, which are less selective markers) will be useful for studies on the functional role of NK cells in vivo as well as their in vivo differentiation and origin from 3.2.3- precursors.

Full Text

The Full Text of this article is available as a PDF (966K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bukowski JF, Warner JF, Dennert G, Welsh RM. Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo. J Exp Med. 1985 Jan 1;161(1):40–52. [PMC free article] [PubMed]
  • Reynolds CW, Bonyhadi M, Herberman RB, Young HA, Hedrick SM. Lack of gene rearrangement and mRNA expression of the beta chain of the T cell receptor in spontaneous rat large granular lymphocyte leukemia lines. J Exp Med. 1985 May 1;161(5):1249–1254. [PMC free article] [PubMed]
  • Lanier LL, Cwirla S, Federspiel N, Phillips JH. Human natural killer cells isolated from peripheral blood do not rearrange T cell antigen receptor beta chain genes. J Exp Med. 1986 Jan 1;163(1):209–214. [PMC free article] [PubMed]
  • Biron CA, van den Elsen P, Tutt MM, Medveczky P, Kumar V, Terhorst C. Murine natural killer cells stimulated in vivo do not express the T cell receptor alpha, beta, gamma, T3 delta, or T3 epsilon genes. J Immunol. 1987 Sep 1;139(5):1704–1710. [PubMed]
  • Ortaldo JR, Sharrow SO, Timonen T, Herberman RB. Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies. J Immunol. 1981 Dec;127(6):2401–2409. [PubMed]
  • Herberman RB. Cell-mediated immunity to tumor cells. Adv Cancer Res. 1974;19(0):207–263. [PubMed]
  • Ortaldo JR, Herberman RB. Heterogeneity of natural killer cells. Annu Rev Immunol. 1984;2:359–394. [PubMed]
  • Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer. 1975 Aug 15;16(2):216–229. [PubMed]
  • Haller O, Hansson M, Kiessling R, Wigzell H. Role of non-conventional natural killer cells in resistance against syngeneic tumour cells in vivo. Nature. 1977 Dec 15;270(5638):609–611. [PubMed]
  • Kiessling R, Wigzell H. An analysis of the murine NK cell as to structure, function and biological relevance. Immunol Rev. 1979;44:165–208. [PubMed]
  • Hanna N, Burton RC. Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo. J Immunol. 1981 Nov;127(5):1754–1758. [PubMed]
  • Barlozzari T, Leonhardt J, Wiltrout RH, Herberman RB, Reynolds CW. Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol. 1985 Apr;134(4):2783–2789. [PubMed]
  • Chambers WH, Vujanovic NL, DeLeo AB, Olszowy MW, Herberman RB, Hiserodt JC. Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med. 1989 Apr 1;169(4):1373–1389. [PMC free article] [PubMed]
  • Sjögren HO, Hellström I. Induction of polyoma specific transplantation antigenicity in Moloney leukemia cells. Exp Cell Res. 1965 Oct;40(1):208–212. [PubMed]
  • DUNN TB, POTTER M. A transplantable mast-cell neoplasm in the mouse. J Natl Cancer Inst. 1957 Apr;18(4):587–601. [PubMed]
  • Julius MH, Simpson E, Herzenberg LA. A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol. 1973 Oct;3(10):645–649. [PubMed]
  • Hünig T, Wallny HJ, Hartley JK, Lawetzky A, Tiefenthaler G. A monoclonal antibody to a constant determinant of the rat T cell antigen receptor that induces T cell activation. Differential reactivity with subsets of immature and mature T lymphocytes. J Exp Med. 1989 Jan 1;169(1):73–86. [PMC free article] [PubMed]
  • Barlozzari T, Reynolds CW, Herberman RB. In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats. J Immunol. 1983 Aug;131(2):1024–1027. [PubMed]
  • Gorelik E, Wiltrout RH, Okumura K, Habu S, Herberman RB. Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer. 1982 Jul 15;30(1):107–112. [PubMed]
  • Young WW, Jr, Hakomori SI, Durdik JM, Henney CS. Identification of ganglio-N-tetraosylceramide as a new cell surface marker for murine natural killer (NK) cells. J Immunol. 1980 Jan;124(1):199–201. [PubMed]
  • Habu S, Hayakawa K, Okumura K, Tada T. Surface markers on natural killer cells of the mouse. Eur J Immunol. 1979 Dec;9(12):938–942. [PubMed]
  • Reynolds CW, Sharrow SO, Ortaldo JR, Herberman RB. Natural killer activity in the rat. II. Analysis of surface antigens on LGL by flow cytometry. J Immunol. 1981 Dec;127(6):2204–2208. [PubMed]
  • Wiltrout RH, Santoni A, Peterson ES, Knott DC, Overton WR, Herberman RB, Holden HT. Reactivity of anti-asialo GM1 serum with tumoricidal and non-tumoricidal mouse macrophages. J Leukoc Biol. 1985 May;37(5):597–614. [PubMed]
  • Riser BL, Laybourn KA, Varani J. Treatment of mice with anti-asialo-GM1 antibody or poly-I:C: effects on metastasis dissociable from modulation of macrophage antitumor activity. Nat Immun Cell Growth Regul. 1988;7(5-6):305–315. [PubMed]
  • Akagawa KS, Maruyama Y, Takano M, Kasai M, Tokunaga T. A cell surface antigen expressed on mouse lung macrophages. Microbiol Immunol. 1981;25(11):1215–1220. [PubMed]
  • Mercurio AM, Schwarting GA, Robbins PW. Glycolipids of the mouse peritoneal macrophage. Alterations in amount and surface exposure of specific glycolipid species occur in response to inflammation and tumoricidal activation. J Exp Med. 1984 Oct 1;160(4):1114–1125. [PMC free article] [PubMed]
  • Suttles J, Schwarting GA, Stout RD. Flow cytometric analysis reveals the presence of asialo GM1 on the surface membrane of alloimmune cytotoxic T lymphocytes. J Immunol. 1986 Mar 1;136(5):1586–1591. [PubMed]
  • Harris MT, Schwarting GA, Stout RD. Selective expression of asialo GM1 on maturational subsets of lymphocytes in normal and athymic mice. Thymus. 1981 Sep;3(3):153–167. [PubMed]
  • Harris MT, Schwarting GA, Stout RD. Expression of asialo GM1 by both Thy-1-positive and Thy-1-negative lymphocytes: evidence for modification of asialo GM1 by sialic acid. Thymus. 1981 Sep;3(3):169–184. [PubMed]
  • Habu S, Fukui H, Shimamura K, Kasai M, Nagai Y, Okumura K, Tamaoki N. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol. 1981 Jul;127(1):34–38. [PubMed]
  • Kasai M, Yoneda T, Habu S, Maruyama Y, Okumura K, Tokunaga T. In vivo effect of anti-asialo GM1 antibody on natural killer activity. Nature. 1981 May 28;291(5813):334–335. [PubMed]
  • Habu S, Shimanura K, Akamatsu K, Okumura K, Tamaoki N. Protective role of natural killer cells in tumor growth and viral infection in mice. Exp Cell Biol. 1984;52(1-2):40–43. [PubMed]
  • Basse P, Hokland P, Heron I, Hokland M. Fate of tumor cells injected into left ventricle of heart in BALB/c mice: role of natural killer cells. J Natl Cancer Inst. 1988 Jul 6;80(9):657–665. [PubMed]
  • Laybourn KA, Hiserodt JC, Abruzzo LV, Varani J. In vitro and in vivo interaction between murine fibrosarcoma cells and natural killer cells. Cancer Res. 1986 Jul;46(7):3407–3412. [PubMed]
  • Silagi S, Dutkowski R, Schaefer A. In vivo requirement for asialo GM1 and Thy1 positive leukocytes for antitumor effect of rIL-2 +/- rIFN-gamma. Anticancer Res. 1988 Nov-Dec;8(6):1265–1269. [PubMed]
  • Pollack SB, Hallenbeck LA. In vivo reduction of NK activity with anti-NK 1 serum: direct evaluation of NK cells in tumor clearance. Int J Cancer. 1982 Feb 15;29(2):203–207. [PubMed]
  • Like AA, Biron CA, Weringer EJ, Byman K, Sroczynski E, Guberski DL. Prevention of diabetes in BioBreeding/Worcester rats with monoclonal antibodies that recognize T lymphocytes or natural killer cells. J Exp Med. 1986 Oct 1;164(4):1145–1159. [PMC free article] [PubMed]
  • Woda BA, Biron CA. Natural killer cell number and function in the spontaneously diabetic BB/W rat. J Immunol. 1986 Sep 15;137(6):1860–1866. [PubMed]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press